Analytical Data
-
基因名
IGHD
- Application
-
别名
IGHD; Immunoglobulin heavy constant delta; Ig delta chain C region; Ig delta chain C region NIG-65; Ig delta chain C region WAH
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01880
-
表达区间
1-576aa
-
氨基酸序列
MGLLHKNMKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCASLGDIYYYGMDVWGQGTTVTVSSAPTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSITCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYLAMTPLIPQSKDENSDDYTTFDDVGSLWTTLSTFVALFILTLLYSGIVTFIKVK
-
分子量
89.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IGHD, or Immunoglobulin Heavy Chain Disease, is a rare genetic disorder characterized by the abnormal rearrangement of heavy chain genes, leading to the production of dysfunctional immunoglobulin proteins. This condition can result in various clinical manifestations, including increased susceptibility to infections and autoimmunity. The study of IGHD recombinant proteins has gained importance as researchers aim to unravel the underlying mechanisms of this disorder and explore potential therapeutic avenues. Recombinant protein technology facilitates the expression of structurally defined immunoglobulin molecules, enabling researchers to analyze their functional properties and interactions with other immune components. Investigating IGHD through recombinant proteins can provide insights into the disease's pathophysiology and contribute to the development of targeted treatment strategies. Additionally, understanding the evolutionary and structural aspects of immunoglobulin heavy chains can enhance our knowledge of immune responses and inform the design of novel immunotherapies. Overall, the research surrounding IGHD recombinant proteins not only aims to decipher the molecular intricacies of this rare disease but also holds promise for advancing immunological research and clinical applications in related fields.
